2020
Neurological safety of oxaliplatin in patients with uncommon variants in Charcot-Marie-tooth disease genes
Le-Rademacher J, Lopez C, Kanwar R, Major-Elechi B, Abyzov A, Banck M, Therneau T, Sloan J, Loprinzi C, Beutler A. Neurological safety of oxaliplatin in patients with uncommon variants in Charcot-Marie-tooth disease genes. Journal Of The Neurological Sciences 2020, 411: 116687. PMID: 32018185, PMCID: PMC7096263, DOI: 10.1016/j.jns.2020.116687.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyRisk of CIPNTooth disease (CMT) genesCIPN riskCharcot-MariePatient-reported outcome instrumentsSingle nucleotide variantsFavor of casesNeurological safetyCommon genetic testsNeurotoxic chemotherapyOxaliplatin therapyPeripheral neuropathyChemotherapy decisionsClinical guidanceOutcome instrumentsUncommon variantPatientsNon-synonymous single nucleotide variantsSignificant associationOxaliplatinGenetic testsRiskCommon single nucleotide variantsCMT
2019
Perspective on potential impact of HIV central nervous system latency on eradication.
Chan P, Ananworanich J. Perspective on potential impact of HIV central nervous system latency on eradication. AIDS 2019, 33 Suppl 2: s123-s133. PMID: 31090545, DOI: 10.1097/qad.0000000000002264.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAntiretroviral therapyEarly antiretroviral therapyHIV antiretroviral therapyLife-long adherencePossibility of comorbidityART interruptionCNS persistenceHIV eradicationNeurological safetyTreatment interruptionHIV remissionNeurocognitive disordersRemission studiesExperimental agentsHIVEradicationTherapyRemissionComorbiditiesAgents
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply